

UCLA

UCLA Previously Published Works

Title

GWAS of the electrocardiographic QT interval in Hispanics/Latinos generalizes previously identified loci and identifies population-specific signals

Permalink

<https://escholarship.org/uc/item/1410j1j5>

Journal

Scientific Reports, 7(1)

ISSN

2045-2322

Authors

Méndez-Giráldez, Raúl
Gogarten, Stephanie M
Below, Jennifer E
et al.

Publication Date

2017

DOI

10.1038/s41598-017-17136-0

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

SCIENTIFIC REPORTS



OPEN

GWAS of the electrocardiographic QT interval in Hispanics/Latinos generalizes previously identified loci and identifies population-specific signals

Raúl Méndez-Giráldez¹, Stephanie M. Gogarten², Jennifer E. Below³, Jie Yao⁴, Amanda A. Seyerle^{1,5}, Heather M. Highland¹, Charles Kooperberg⁶, Elsayed Z. Soliman^{7,8}, Jerome I. Rotter⁴, Kathleen F. Kerr², Kelli K. Ryckman⁹, Kent D. Taylor⁴, Lauren E. Petty^{10,11}, Sanjiv J. Shah¹², Matthew P. Conomos², Nona Sotoodehnia^{13,14}, Susan Cheng¹⁵, Susan R. Heckbert^{13,16}, Tamar Sofer^{2,17,18}, Xiuqing Guo⁴, Eric A. Whitsel^{1,19}, Henry J. Lin^{4,20}, Craig L. Hanis¹⁰, Cathy C. Laurie² & Christy L. Avery^{1,21}

QT interval prolongation is a heritable risk factor for ventricular arrhythmias and can predispose to sudden death. Most genome-wide association studies (GWAS) of QT were performed in European ancestral populations, leaving other groups uncharacterized. Herein we present the first QT GWAS of Hispanic/Latinos using data on 15,997 participants from four studies. Study-specific summary results of the association between 1000 Genomes Project (1000G) imputed SNPs and electrocardiographically measured QT were combined using fixed-effects meta-analysis. We identified 41 genome-wide significant SNPs that mapped to 13 previously identified QT loci. Conditional analyses distinguished six secondary signals at *NOS1AP* ($n = 2$), *ATP1B1* ($n = 2$), *SCN5A* ($n = 1$), and *KCNQ1* ($n = 1$). Comparison of linkage disequilibrium patterns between the 13 lead SNPs and six secondary signals with previously reported index SNPs in 1000G super populations suggested that the *SCN5A* and *KCNE1* lead SNPs were potentially novel and population-specific. Finally, of the 42 suggestively associated loci, *AJAP1*

¹Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA. ²Department of Biostatistics, University of Washington, Seattle, WA, USA. ³The Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. ⁴The Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA. ⁵Division of Epidemiology and Community, University of Minnesota, Minneapolis, MN, USA. ⁶Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ⁷Department of Internal Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, NC, USA. ⁸Epidemiological Cardio Research Center (EPICARE), Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA. ⁹Departments of Epidemiology and Pediatrics, University of Iowa, Iowa City, IA, USA. ¹⁰Human Genetics Center, University of Texas, Health Science Center at Houston, Houston, TX, USA. ¹¹Center for Precision Medicine, University of Texas, Health Science Center at Houston, Houston, TX, USA. ¹²Division of Cardiology, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. ¹³Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA. ¹⁴Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA. ¹⁵Brigham and Women's Hospital, Division of Cardiovascular Medicine, Boston, MA, USA. ¹⁶Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁷Department of Medicine, Harvard Medical School, Boston, MA, USA. ¹⁸Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA, USA. ¹⁹Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. ²⁰Division of Medical Genetics, Harbor-UCLA Medical Center, Torrance, CA, USA. ²¹Carolina Population Center, University of North Carolina, Chapel Hill, NC, USA. Correspondence and requests for materials should be addressed to R.M.-G. (email: rmendez@email.unc.edu) or C.L.A. (email: christy_avery@unc.edu)

was suggestively associated with QT in a prior East Asian GWAS; in contrast *BVES* and *CAP2* murine knockouts caused cardiac conduction defects. Our results indicate that whereas the same loci influence QT across populations, population-specific variation exists, motivating future trans-ethnic and ancestrally diverse QT GWAS.

The QT interval (QT), as measured by the resting 12-lead electrocardiogram (ECG), provides a non-invasive assessment of ventricular repolarization, the prolongation or shortening of which is an established risk factor for a spectrum of cardiovascular diseases, including sudden cardiac death (SCD)¹. Although SCD accounts for roughly 10–20% of total mortality in industrial countries, prevention and treatment remains incomplete, resulting in a majority of cases occurring in the absence of clinical features that would elicit medical attention². Additional efforts to understand underlying biology are therefore needed.

QT genome-wide association studies (GWAS) provide a means at informing SCD biology, if not prevention and treatment³, because approximately 10% SCD cases are caused by *torsades de pointes*⁴. QT also is heritable⁵ and reliably measured⁶. Moreover, GWAS-identified QT SNPs have been associated with a >30% increase in risk of SCD, results replicated by some studies^{7,8}, but not others^{9,10}. In contrast, SCD GWAS have been difficult to perform, likely reflecting the small sample sizes, phenotypic heterogeneity, and outcome measurement error that characterize existing studies¹¹, therefore resulting in a limited number of loci identified to-date^{7,12}. Together, these findings motivate additional, well-powered GWAS of QT to improve understanding of QT prolongation and SCD.

Currently a majority of GWAS of QT have been conducted in populations of European ancestry^{13–19}, although modestly sized studies of African Americans^{20,21} and East Asians^{22,23} also have been published. Few QT GWAS have included Hispanic/Latino populations, which will constitute 31% of the U.S. population by 2060²⁴ and shoulder increased burdens of QT prolonging and SCD-predisposing obesity and diabetes as compared to European ancestral populations^{25,26}. Here we present the first QT GWAS of Hispanic/Latinos.

Results

This GWAS included 15,997 individuals of Hispanic/Latino ancestry from four cohorts ranging in size from 883 to 11,932 participants. Study participants were predominantly female (64%), middle aged (mean = 49 years), and obese (mean body mass index = 30 kg/m²) (Supplementary Table 1). The prevalence of diabetes ranged from 8.0% (Women's Health Initiative, WHI) to 45.6% (Starr County, reflecting a study design with approximately equal proportions of participants with and without diabetes).

Genome-wide Association Analysis. After study-specific quality control and filtering by effective sample size (see Methods), studies contributed between 5,997,534 (Starr County) and 17,322,742 (Hispanic Community Health Study/Study of Latinos, HCHS/SOL) imputed SNPs (Supplementary Table 2), which together represented 17,586,686 unique SNPs. A total of 41 SNPs at 13 of the 35 previously identified QT loci¹⁹ were genome wide significant (Fig. 1, Table 1 and Supplementary Table 3), with no evidence of genomic inflation (study-specific λ range: 0.98–1.02, Supplementary Figures 1 and 2; $\lambda = 1.01$). A total of 42 suggestive loci ($P\text{-val} < 5 \times 10^{-6}$) were also identified (Supplementary Table 4); notably, 26 of the 42 suggestive loci only passed the effective sample size filter in the HCHS/SOL study, likely reflecting their rarity (i.e. minor allele frequency [MAF] < 0.05). Both genome-wide significant and suggestive loci demonstrated wide variation in minor allele frequency across ancestries (Supplementary Tables 3, 4), although very limited reporting of suggestive loci or publication of GWAS summary statistics from imputed data limited comprehensive evaluation of suggestive loci.

For the 13 lead (i.e. locus-specific and most significant) SNPs in previously detected QT loci, little evidence of heterogeneity among studies was detected (Cochran's Q test $P\text{-val} > 0.05$) and study-specific estimates exhibited directional consistency in estimated effects with the exception of rs12626657 at the *KCNE1* locus. Eleven of the 13 lead SNPs were correlated ($r^2 > 0.20$; Supplemental Table 5; LD calculated separately in 1000G African [AFR], Ad Mixed American [AMR], East Asian [ASN], and European [EUR] super populations) with previously reported genome-wide significant index SNPs. However, the *SCN5A* (rs3922844) and *KCNE1* (rs12626657) Hispanic/Latino lead SNPs demonstrated little correlation with previously reported QT lead SNPs. *KCNE1* lead SNP rs12626657 (Hispanic/Latino MAF = 0.15, Table 1) also was monomorphic in the EUR 1000 Genomes super population.

Sequential conditional analysis (see Methods) identified four loci with evidence of secondary signals (i.e. SNPs that were uncorrelated with lead SNPs, Table 2): *NOS1AP* (Fig. 2; two secondary signals, rs3934467 and rs73017364), *ATP1B1* (Fig. 3; two secondary signals, rs1320977 and rs1138486), *SCN5A* (Fig. 4; one secondary signal, rs6762565), and *KCNQ1* (Fig. 5; one secondary signal, rs78695585). All six secondary signals at these four loci were correlated ($r^2 > 0.20$) with previously identified lead SNPs in the European 1000G super-population (Supplementary Table 5). Wide variation in the linkage disequilibrium (LD) structure for the secondary signals also was observed. For example, SNPs correlated ($r^2 > 0.20$; Supplementary Table 5) with the *ATP1B1* lead SNPs and secondary signals spanned ~400 kb (Fig. 3). In contrast, the secondary signals at *NOS1AP*, *SCN5A*, and *KCNQ1* (Figs 2, 4, and 5) were characterized by fewer correlated SNPs and narrower flanking intervals. (See Supplementary Figure 3 for locus zoom plots for genome wide significant loci without evidence of secondary signals).

Generalization analysis. Next we evaluated 34 index SNPs reported as genome-wide significant by the largest QT GWAS published to-date in up to 103,000 European ancestry individuals¹⁹. A total of 27 of the 34 (79%) previously identified index SNPs generalized to Hispanic/Latinos ($r\text{-value} < 0.05$) (Supplementary Figure 4), with

Locus	Lead SNP	Chr	Position (hg19)	A1	A2	CAF	β (ms)	Direction of β	SE (ms)	P-val	P_{het}
<i>RNF207</i>	rs7531322	1	6,299,823	C	G	0.30	1.73	++++	0.24	1.04e-12	0.17
<i>NOS1AP</i>	rs12143842	1	162,033,890	T	C	0.22	3.46	++++	0.25	3.30e-42	0.35
<i>ATP1B1</i>	rs12035622	1	169,102,340	A	T	0.19	-2.36	----	0.27	8.77e-18	0.73
<i>SLC8A1</i>	rs35450971	2	40,754,314	T	C	0.79	1.71	++++	0.26	8.37e-11	0.45
<i>TTN</i>	rs55863869	2	179,647,546	A	G	0.84	-1.92	----	0.30	2.40e-10	0.42
<i>SCN5A</i>	rs3922844	3	38,624,253	T	C	0.37	1.77	++++	0.22	9.52e-16	0.06
<i>SLC35F1</i>	rs2078383	6	118,706,643	T	C	0.25	1.83	++++	0.25	2.07e-13	0.82
<i>KCNH2</i>	rs35760656	7	150,658,678	A	G	0.35	1.70	++++	0.23	4.21e-13	0.50
<i>KCNQ1</i>	rs12271931	11	2,478,519	A	G	0.93	3.92	??++	0.57	4.07e-12	0.13
<i>LITAF</i>	rs735951	16	11,693,536	A	G	0.41	-1.55	----	0.22	5.92e-13	0.78
<i>SETD6</i>	rs185639574	16	58,550,052	T	G	0.34	-2.53	----	0.24	6.67e-27	0.52
<i>PRKCA</i>	rs56152251	17	64,280,153	A	G	0.44	-1.60	----	0.21	6.64e-14	0.85
<i>KCNE1</i>	rs12626657	21	35,828,173	A	G	0.15	2.69	+++-	0.31	1.14e-17	0.01

Table 1. Genome-wide significant loci identified in a GWAS meta-analysis of $n = 15,997$ participants of Hispanic/Latino ancestry from four studies, that were previously reported. Chr: chromosome number. Position: base pair position in Build 37 (hg19). A1, A2: coded/non-coded alleles. β : effect estimate in ms. Direction of β : direction of the effect estimates per study following this order: WHI, MESA, HCHS/SOL and Starr County; '?' means the SNP is not present in that particular study. SE: standard error. P_{het} : P-val for Cochran's Q test of homogeneity among cohorts.

Locus	SNP	Chr	Position (hg19)	A1	A2	CAF	β (ms)	Direction of β	SE (ms)	P-val	P_{het}
<i>NOS1AP</i>	rs3934467	1	162,182,677	T	C	0.28	1.62	++++	0.24	2.26e-11	0.78
	rs73017364	1	162,184,746	T	C	0.87	1.73	++++	0.31	3.74e-08	0.65
<i>ATP1B1</i>	rs1320977	1	169,073,388	A	G	0.15	-2.30	----+	0.29	2.61e-15	0.02
	rs1138486	1	169,101,935	T	C	0.14	-2.46	----?	0.31	6.98e-15	0.55
<i>SCN5A</i>	rs6762565	3	38,582,191	T	C	0.19	-1.65	?--?	0.29	1.94e-08	0.19
<i>KCNQ1</i>	rs78695585	11	2,644,544	A	G	0.04	3.48	++++	0.59	2.82e-09	0.63

Table 2. Genome-wide significant secondary SNPs from previously reported regions, identified in meta-analyzed conditional analysis. Chr: chromosome number. Position: the base pair position in Build 37 (hg19). A1, A2: coded/non-coded alleles. CAF: coded allele frequency. β : effect estimate in ms for the highest associated SNP upon conditional analysis. Direction: the direction of the effect estimates; order is WHI, MESA, HCHS/SOL, and Starr County; '?' means the SNP was not present for a particular study. SE: standard error (ms). P_{het} : P-val for Cochran's Q test of homogeneity among cohorts, for the highest associated SNP upon conditional analysis.




Figure 1. Manhattan plot of results from QT GWAS of 15,997 participants of Hispanic/Latino ancestry. The y-axis represents $-\log_{10}(P\text{-value})$ and truncated at 25. SNPs, ordered by chromosome and position, are shown on the x-axis. Significant loci are labelled as the nearest gene.

effects similar to those in the original GWAS. Of note, eight of the 27 index SNPs that generalized also were associated with QT in Hispanic/Latinos at genome-wide significant levels (*RNF207*, *NOS1AP*, *ATP1B1*, *SLC8A1*, *SLC35F1*, *KCNQ1*, *LITAF*, and *SETD6*). Among the seven index SNPs that did not generalize at the *KCNJ2*,




Figure 2. Locus zoom plots of the *NOS1AP* gene region showing SNP p-values from the primary (A) and conditional analyses (B,C). The lead SNP in the primary analysis is the previously reported rs12143842 (panel A), the secondary lead SNP after conditioning on rs12143842 is rs3934467 (panel B), and the secondary lead SNP after conditioning on rs12143842 and rs3934467 simultaneously is rs73017364 (panel C).




Figure 3. Locus zoom plots of the *ATP1B1* gene region providing p-values from the primary (A) and conditional analyses (B,C). The lead SNP in the primary analysis is the previously reported rs12035622 (panel A), the secondary lead SNP after conditioning on rs12035622 is rs1320977 (panel B), and the secondary signal after conditioning on rs12035622 and rs1320977 simultaneously, is rs1138486 (panel C).




Figure 4. Locus zoom plots of the *SCN5A* gene region providing p-values from the primary (A) and conditional analyses (B). The lead SNP in the primary analysis is the previously reported rs13922844 (panel A), and the secondary lead SNP after conditioning on rs13922844 is rs6762565 (panel B).




Figure 5. Locus zoom plots of the *KCNQ1* gene region providing p-values from the primary (A) and conditional (B) analyses. The lead SNP in the primary analysis is the previously reported rs12271931 (panel A), and the secondary lead SNP after conditioning on rs12271931 is rs78695585 (panel B).

C3ORF75, *GFRA3*, *GMPR*, *CAV1*, *AZIN1*, and *ANKRD9* loci, the consistency in directions of estimated associations between the HCHS/SOL and Arking *et al.*¹⁹ is higher than what is expected by chance (p-value = 0.01 on a binomial test), suggesting that at least some of the variants that did not generalize are in fact associated with QT in Hispanics/Latinos and that non-generalization was due to lack of power (Supplementary Figure 4 and Supplementary Table 6).

Bioinformatic characterization. For several of the genome-wide significant SNPs associated, we identified strong experimental evidence for transcriptional activation in heart tissue, including the *ATP1B1*, *TTN*, *SCN5A*, and *KCNH2* loci. Conversely, *SLC35F1*, *SETD6* and *KCNE1* had weaker evidence for transcriptional activation; and *NOS1AP*, *KCNQ1* and *LITAF* had epigenetic marks identifying them as putative enhancers of gene transcription. (See Supplementary Table 7 for additional results of bioinformatic characterization).

Discussion

In this investigation, the first GWAS of Hispanic/Latinos, we identified 13 loci associated with QT at the genome-wide significant thresholds. Although all genome-wide significant loci were reported in earlier QT GWAS^{13,15–17,19–22}, we also identified potential evidence of novel and population-specific SNPs at the *SCN5A* and *KCNE1* loci. Further, we reported several suggestive and biologically plausible loci as promising candidates for future follow-up. Together, our results underscore the utility of extending GWAS to include currently under-represented populations to enable improved characterization of the genomics of complex traits like QT.

The majority of participants included in GWAS to-date, including QT GWAS, are of European descent^{27,28}, which limits the relevance of medical genomics globally and fails to leverage human diversity to identify novel loci and improve fine-mapping resolution. Hispanics/Latinos – long understudied in large scale genomics efforts – may be particularly informative for QT GWAS due to an increased prevalence of QT-prolonging and SCD-predisposing obesity and diabetes^{25,29}. Indeed, loci common to QT, obesity, and diabetes have been identified (e.g. *KCNQ1*)^{30,31}. Further, while studies have reported a decreased SCD incidence in Hispanic/Latinos compared to African Americans or European Americans^{32,33}, these discordant observations – consistent with the “Hispanic paradox” of lower cardiovascular disease risk despite higher risk factor levels – may reflect ethnic misclassification, selective migration and incomplete cause of death ascertainment rather than decreased SCD incidence^{34–38}. In addition to shouldering a greater burden of QT-increasing risk factors, Hispanic/Latino

populations are composed of differing proportions of European, African, and Amerindian ancestry³⁹. Therefore, including Hispanics/Latinos in GWAS allows examination of SNPs that may be uncommon, rare, or absent in other populations. For example, the *KCNE1* index SNP rs12626657, which appeared to be population-specific, was monomorphic in European populations, but is common in AMR and ASN populations. Thus, the overarching genetic architecture and risk factor profiles of Hispanic/Latino populations may be uniquely positioned to inform the biology underlying QT prolongation and its downstream consequences, e.g. SCD.

Despite the expected benefits of studying Hispanic/Latinos for mapping novel QT loci, our novel genome-wide significant findings were limited to the identification of two potentially population-specific SNPs at established loci. Interestingly, *SCN5A* lead SNP rs3922844 was identified as the lead SNP in PR interval⁴⁰ and QRS⁴¹ GWAS in African American populations. Thus, while the same loci may influence QT across global populations, ancestrally specific SNPs also exist. Limited success mapping novel loci may reflect several factors including sample size. Yet, several suggestive and biologically plausible loci deserve mention, particularly *AJAPI*, *CAP2*, and *BVES*. For example, a prior QT GWAS in East Asian populations also reported that SNPs at the *AJAPI* locus, a chromosomal region with few ties to cardiac conduction, were suggestively associated with QT²². *CAP2*, located approximately one mega base from the previously described *GMPR* QT locus¹⁹, also is commonly deleted in 6p22 syndrome, a condition characterized by developmental delays and heart defects^{42,43}. Interestingly, *CAP2* murine knockouts developed cardiac conduction defects, leading to sudden cardiac death from complete heart block⁴⁴. Finally, an effort using epigenomic signatures to validate loci suggestively associated with QT¹⁹ reported that mice homozygous for loss-of-function *BVES* alleles exhibited cardiac conduction and pacemaker defects. Knockdown of *bves* in zebrafish also produced shortening of the action potential duration, a QT correlate⁴⁵.

Clearly *AJAPI*, *CAP2*, and *BVES* remain suggestive until formal replication is achieved. Yet, it is important to again highlight the wide variation in minor allele frequencies observed across global populations. Thus, in the absence of an independent, large population of Hispanic/Latinos with the requisite genotype and electrocardiographic characterization, future attempts at replication and novel locus identification should consider multi-ethnic populations of European, African, and Amerindian descent given the tri-admixed nature of Hispanic/Latinos populations³⁹. Indeed, further advances in genotype arrays designed to capture African and Amerindian-specific content, combined with improved reference panels, will likely enable large trans-ethnic meta-analyses, thereby negating the current practice of race/ethnic-specific analyses. Trans-ethnic GWAS also would be valuable for locus refinement and fine-mapping, given that several loci, including *ATP1B1*, remain prohibitively large in size, making identification of underlying functional variants difficult. Further potentially fruitful avenues of inquiry also could include evaluation of exome or whole-genome sequencing data, given the existence of highly penetrant mutations for QT⁴⁶, which have undergone limited characterization in diverse racial/ethnic populations despite repeated calls for greater diversity in large-scale genomics research⁴⁷.

Despite many strengths, this work had several limitations that deserve consideration. The main limitation of our work is sample size, given that prior QT GWAS in European ancestral populations had sample sizes that for some loci that exceeded 100,000 participants. Yet, we successfully generalized 79% of previously identified loci, despite a considerably smaller sample size. Evidence of population-specific signals and biologically plausible suggestive loci not previously detected by prior large GWAS further underscore the value of examining under-represented populations. Second, generalizability of study results to Hispanic/Latinos is unknown. However, studies such as the HCHS/SOL included large samples of Hispanic/Latino participants from diverse countries of origin, helping to ensure that relatively broad representation was achieved. Finally, similar to a previously published African American QT GWAS²⁰, our study participants were predominantly female and obese, with a high prevalence of diabetes. It is unclear how these characteristics, known to affect QT^{25,26,48}, might have affected study findings or the ability to compare results across populations with differing characteristics.

In summary, our meta-analysis of four Hispanic/Latino populations generalized a majority of the previously identified QT loci, thereby demonstrating the global relevance of these loci. We also detected novel and potentially population-specific signals, one of which was monomorphic in European populations and another that has been reported in GWAS of other cardiac conduction traits in African Americans, possibly indicating population-specific variation in the genetic architecture underlying QT. Finally, we reported several highly promising and biologically plausible suggestive loci not identified in previous GWAS with substantially larger sample sizes. There is a delicate balance between the use of QT measurements tailored to particular subpopulations versus their generalization to the general population to prevent TdP and/or prescribing drugs that minimize the risk of causing the latter, as pointed by Diemberger *et al.*⁴⁹ and Poluzzi *et al.*⁵⁰. Together, these findings underscore the utility of including genetic data of diverse racial/ethnic groups within GWAS in an attempt to better understand the genetic architecture of complex phenotypes like QT.

Methods

Study populations. This meta-analysis included 15,997 participants of Hispanic/Latino descent from the following four studies: the HCHS/SOL (n = 11,932)^{51,52}, the Multi-Ethnic Study of Atherosclerosis (MESA, n = 1,431)⁵³, Starr County Study (n = 883)⁵⁴, and the WHI (n = 1,751)⁵⁵ (see Supplementary Materials and Methods).

Electrocardiography. Within each cohort, ECGs were recorded by certified technicians using standard 12-lead apparatus and protocols. In the case of HCHS/SOL, MESA and WHI, the QT duration is the maximum time in ms between the earliest onset of the QRS complex to the latest offset of the T wave among the median QT intervals across all 12 leads (see Supplementary Table 2). Participants with poor quality ECGs, atrial flutter or fibrillation on ECG, intraventricular conduction delay, a paced rhythm, or a QRS duration ≥ 120 were excluded from analysis.

Genotyping and imputation. Participants were genotyped on either the Affymetrix Genome-Wide Human SNP Array 6.0 (MESA, Starr County, and WHI) or an Illumina custom array that consisted of the Illumina Omni 2.5 M array (HumanOmni 2.5-8v1-1) and ~150,000 custom SNPs selected to include ancestry-informative markers, variants characteristic of Native American populations, previously identified GWAS loci, and other candidate gene polymorphisms (HCHS/SOL)³⁹ (Supplementary Table 2). Following study-specific genotype QC (Supplementary Table 2), imputation was performed for approximately 38 million SNPs based on the 1000G phase 1 reference panel⁵⁶.

Statistical Analysis. A maximum of 17,586,686 imputed SNPs (Supplementary Table 2 for details) were examined for associations with QT under an additive genetic model using linear regression (MESA, Starr County, and WHI) or linear mixed models (HCHS/SOL)³⁹. The association of each SNP with QT was adjusted for age, sex, heart rate, ancestral principal components, and study site/region, when appropriate, to maintain consistency with previously published QT GWAS¹⁹. Associations in the HCHS/SOL study were further adjusted for beta-blocking medication use, a significant predictor of QT in HCHS/SOL, sampling weights, and genetic analysis group³⁹.

We excluded SNPs that either mapped to the same base pair position or the same rsid, identified using the UCSC Table browser (<https://genome.ucsc.edu/cgi-bin/hgTables>). We also excluded SNPs with imputation quality metrics <0.3 or with small effective sample sizes ($effN < 30$), defined within each study for each SNP as: $effN = 2 \times MAF \times (1 - MAF) \times N \times Imputation\ Quality$; where N is the number of participants. Fixed-effects inverse variance meta-analysis was then performed using METAL⁵⁷ on genomically controlled study-specific summary statistics to combine effect estimates (β coefficients) and standard errors (SE). Heterogeneity among studies was assessed by Cochran' Q test. Complete meta-analysis results are available on dbGAP (<https://www.ncbi.nlm.nih.gov/gap>) with accession number phs000930.

Genome wide significant associations were defined as SNPs with P-value < 5×10^{-8} (Bonferroni correction for ~ 10^6 independent variants). Suggestive associations were those with P-val < 5×10^{-6} . To identify secondary signals, we performed sequential conditional analyses by adjusting for significant Hispanic/Latino lead SNPs until no remaining genome-wide significant SNPs remained. Population-specific SNPs were defined as SNPs in low LD ($r^2 < 0.20$)^{58,59} with previously reported SNPs in the population in which the SNP was discovered [using 1000G Project phase-1⁶⁰ summary results (EUR, AMR, AFR, ASN) and the Application Program Interface (API) in Perl provided by ENSEMBL (http://useast.ensembl.org/info/docs/api/variation/variation_tutorial.html)].

Generalization. For SNPs previously reported as significantly associated with QT in published GWAS (i.e. P-value < 5×10^{-8}), we used the approach by Sofer *et al.* to examine evidence for generalization⁶¹, i.e. the replication of SNP-phenotype associations in a population with different ancestry than the population in which the associations were first identified. Briefly, Sofer *et al.*'s approach assigned an r-value to every index SNP, and the generalization null hypothesis testing generalization of the QT index SNPs to Hispanic/Latinos was rejected when the r-value < 0.05, controlling the false discovery rate. For each SNP, we presented confidence intervals of the association effect in the discovery study¹⁹ alongside confidence intervals of the effect in Hispanic/Latino populations.

Functional Annotation. We used epigenetic data from the ENCODE⁶² and RoadMap⁶³ projects to functionally annotate significant loci (lead SNP, secondary signals, and any SNPs in high LD ($r^2 > 0.80$) with lead SNPs or secondary signals in Hispanic/Latinos) using the HaploReg v4.1 on-line resource⁶⁴ and the Chromatin 15-state model, based on ChromHMM provided within the latter. Functional annotation was restricted to heart tissue (fetal heart, right and left atrium and left ventricle). Although the LD pattern used in HaploReg v4.1 is based on the AMR 1000G Phase-1 super-population, the data on ENCODE and RoadMap come from individuals of heterogeneous (or unknown) ancestry (<https://docs.google.com/spreadsheets/d/1yikGx4MsO9Ei36b-64yOy9Vb6oPC51BGLFbYEt-N6gOM/edit#gid=15>). In addition to the summary of the functional annotation results, Supplementary Table 8 provides biological function and previously known polymorphisms for the 13 genome-wide significant loci associated with QT in Hispanic/Latinos.

References

- Zhang, Y. *et al.* QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. *Arch Intern Med* **171**, 1727–1733, <https://doi.org/10.1001/archinternmed.2011.433> (2011).
- Chung, H. *et al.* Frequency and type of seafood consumed influence plasma (n-3) fatty acid concentrations. *The Journal of nutrition* **138**, 2422–2427, <https://doi.org/10.3945/jn.108.089631> (2008).
- Chugh, S. S. *et al.* Epidemiology of sudden cardiac death: clinical and research implications. *Prog Cardiovasc Dis* **51**, 213–228, <https://doi.org/10.1016/j.pcad.2008.06.003> (2008).
- Israel, C. W. Mechanisms of sudden cardiac death. *Indian Heart J* **66**(Suppl 1), S10–17, <https://doi.org/10.1016/j.ihj.2014.01.005> (2014).
- Newton-Cheh, C. *et al.* QT interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: The Framingham Heart Study. *Heart Rhythm* **2**, 277–284, <https://doi.org/10.1016/j.hrthm.2004.11.009> (2005).
- Vaidean, G. D. *et al.* Short-term repeatability of electrocardiographic spatial T-wave axis and QT interval. *J Electrocardiol* **38**, 139–147, <https://doi.org/10.1016/j.jelectrocard.2004.09.020> (2005).
- Arking, D. E. *et al.* Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals. *PLoS Genet* **7**, e1002158, <https://doi.org/10.1371/journal.pgen.1002158> (2011).
- Ritchie, M. D. *et al.* Genome- and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. *Circulation* **127**, 1377–1385, <https://doi.org/10.1161/CIRCULATIONAHA.112.000604> (2013).
- Noseworthy, P. A. *et al.* Common genetic variants, QT interval, and sudden cardiac death in a Finnish population-based study. *Circ Cardiovasc Genet* **4**, 305–311, <https://doi.org/10.1161/CIRCGENETICS.110.959049> (2011).
- Pazoki, R. *et al.* SNPs identified as modulators of ECG traits in the general population do not markedly affect ECG traits during acute myocardial infarction nor ventricular fibrillation risk in this condition. *PLoS One* **8**, e57216, <https://doi.org/10.1371/journal.pone.0057216> (2013).

11. Marsman, R. F., Tan, H. L. & Bezzina, C. R. Genetics of sudden cardiac death caused by ventricular arrhythmias. *Nature reviews. Cardiology* **11**, 96–111, <https://doi.org/10.1038/nrcardio.2013.186> (2014).
12. Bezzina, C. R. *et al.* Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. *Nat Genet* **42**, 688–691, <https://doi.org/10.1038/ng.623> (2010).
13. Arking, D. E. *et al.* A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. *Nat Genet* **38**, 644–651, <https://doi.org/10.1038/ng1790> (2006).
14. Newton-Cheh, C. *et al.* Genome-wide association study of electrocardiographic and heart rate variability traits: the Framingham Heart Study. *BMC Med Genet* **8**(Suppl 1), S7, <https://doi.org/10.1186/1471-2350-8-S1-S7> (2007).
15. Marroni, F. *et al.* A genome-wide association scan of RR and QT interval duration in 3 European genetically isolated populations: the EUROSPAN project. *Circ Cardiovasc Genet* **2**, 322–328, <https://doi.org/10.1161/circgenetics.108.833806> (2009).
16. Newton-Cheh, C. *et al.* Common variants at ten loci influence QT interval duration in the QTGEN Study. *Nat Genet* **41**, 399–406, <https://doi.org/10.1038/ng.364> (2009).
17. Nolte, I. M. *et al.* Common genetic variation near the phospholamban gene is associated with cardiac repolarisation: meta-analysis of three genome-wide association studies. *PLoS One* **4**, e6138, <https://doi.org/10.1371/journal.pone.0006138> (2009).
18. Holm, H. *et al.* Several common variants modulate heart rate, PR interval and QRS duration. *Nat Genet* **42**, 117–122, <https://doi.org/10.1038/ng.511> (2010).
19. Arking, D. E. *et al.* Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. *Nat Genet* **46**, 826–836, <https://doi.org/10.1038/ng.3014> (2014).
20. Smith, J. G. *et al.* Impact of ancestry and common genetic variants on QT interval in African Americans. *Circ Cardiovasc Genet* **5**, 647–655, <https://doi.org/10.1161/CIRCGENETICS.112.962787> (2012).
21. Jeff, J. M. *et al.* Generalization of variants identified by genome-wide association studies for electrocardiographic traits in African Americans. *Ann Hum Genet* **77**, 321–332, <https://doi.org/10.1111/ahg.12023> (2013).
22. Kim, J. W. *et al.* A common variant in SLC8A1 is associated with the duration of the electrocardiographic QT interval. *Am J Hum Genet* **91**, 180–184, <https://doi.org/10.1016/j.ajhg.2012.05.019> (2012).
23. Sano, M. *et al.* Genome-wide association study of electrocardiographic parameters identifies a new association for PR interval and confirms previously reported associations. *Hum Mol Genet* **23**, 6668–6676, <https://doi.org/10.1093/hmg/ddu375> (2014).
24. Sandra, L. & Colby, J. M. O. Projections of the Size and Composition of the U.S. Population: 2014 to 2060. (U.S. Census Bureau, Economics and Statistics Administration, U.S. Department of Commerce 2015).
25. el-Gamal, A. *et al.* Effects of obesity on QT, RR, and QTc intervals. *Am J Cardiol* **75**, 956–959 (1995).
26. Balkau, B., Jouven, X., Ducimetiere, P. & Eschwege, E. Diabetes as a risk factor for sudden death. *Lancet* **354**, 1968–1969, [https://doi.org/10.1016/S0140-6736\(99\)04383-4](https://doi.org/10.1016/S0140-6736(99)04383-4) (1999).
27. Bustamante, C. D., Burchard, E. G. & De la Vega, F. M. Genomics for the world. *Nature* **475**, 163–165, <https://doi.org/10.1038/475163a> (2011).
28. Mahida, S. *et al.* Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives. *Journal of interventional cardiac electrophysiology: an international journal of arrhythmias and pacing* **37**, 9–19, <https://doi.org/10.1007/s10840-013-9779-5> (2013).
29. Whitsel, E. A. *et al.* Electrocardiographic QT interval prolongation and risk of primary cardiac arrest in diabetic patients. *Diabetes Care* **28**, 2045–2047 (2005).
30. Voight, B. F. *et al.* Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet* **42**, 579–589, <https://doi.org/10.1038/ng.609> (2010).
31. Wen, W. *et al.* Meta-analysis of genome-wide association studies in East Asian-ancestry populations identifies four new loci for body mass index. *Hum Mol Genet* **23**, 5492–5504, <https://doi.org/10.1093/hmg/ddu248> (2014).
32. Gillum, R. F., Makuc, D. M. & Feldman, J. J. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. *American heart journal* **121**, 172–177 (1991).
33. Zheng, Z. J., Croft, J. B., Giles, W. H. & Mensah, G. A. Sudden cardiac death in the United States, 1989 to 1998. *Circulation* **104**, 2158–2163 (2001).
34. Hunt, K. J. *et al.* All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older participants in the San Antonio Heart Study- evidence against the “Hispanic paradox”. *Am J Epidemiol* **158**, 1048–1057 (2003).
35. Crimmins, E. M., Kim, J. K., Alley, D. E., Karlamangla, A. & Seeman, T. Hispanic paradox in biological risk profiles. *American journal of public health* **97**, 1305–1310, <https://doi.org/10.2105/AJPH.2006.091892> (2007).
36. Razum, O., Zeeb, H. & Rohrmann, S. The ‘healthy migrant effect’—not merely a fallacy of inaccurate denominator figures. *International journal of epidemiology* **29**, 191–192 (2000).
37. Huh, J., Prause, J. A. & Dooley, C. D. The impact of nativity on chronic diseases, self-rated health and comorbidity status of Asian and Hispanic immigrants. *Journal of immigrant and minority health/Center for Minority Public Health* **10**, 103–118, <https://doi.org/10.1007/s10903-007-9065-7> (2008).
38. Palloni, A. & Arias, E. Paradox lost: explaining the Hispanic adult mortality advantage. *Demography* **41**, 385–415 (2004).
39. Conomos, M. P. *et al.* Genetic Diversity and Association Studies in US Hispanic/Latino Populations: Applications in the Hispanic Community Health Study/Study of Latinos. *Am J Hum Genet* **98**, 165–184, <https://doi.org/10.1016/j.ajhg.2015.12.001> (2016).
40. Smith, J. G. *et al.* Genome-wide association studies of the PR interval in African Americans. *PLoS genetics* **7**, e1001304, <https://doi.org/10.1371/journal.pgen.1001304> (2011).
41. Evans, D. S. *et al.* Fine-mapping, novel loci identification, and SNP association transferability in a genome-wide association study of QRS duration in African Americans. *Hum Mol Genet*, <https://doi.org/10.1093/hmg/ddw284> (2016).
42. Bremer, A., Schoumans, J., Nordenskjold, M., Anderlid, B. M. & Giacobini, M. An interstitial deletion of 7.1 Mb in chromosome band 6p22.3 associated with developmental delay and dysmorphic features including heart defects, short neck, and eye abnormalities. *Eur J Med Genet* **52**, 358–362, <https://doi.org/10.1016/j.ejmg.2009.06.002> (2009).
43. Ono, S. The role of cyclase-associated protein in regulating actin filament dynamics - more than a monomer-sequestration factor. *J Cell Sci* **126**, 3249–3258, <https://doi.org/10.1242/jcs.128231> (2013).
44. Field, J. *et al.* CAP2 in cardiac conduction, sudden cardiac death and eye development. *Sci Rep* **5**, 17256, <https://doi.org/10.1038/srep17256> (2015).
45. Wang, X. *et al.* Discovery and validation of sub-threshold genome-wide association study loci using epigenomic signatures. *Elife* **5**, <https://doi.org/10.7554/eLife.10557> (2016).
46. Mathias, A. *et al.* Prognostic implications of mutation-specific QTc standard deviation in congenital long QT syndrome. *Heart Rhythm* **10**, 720–725, <https://doi.org/10.1016/j.hrthm.2013.01.032> (2013).
47. Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* **538**, 161–164, <https://doi.org/10.1038/538161a> (2016).
48. Lepeschkin, E. & Surawicz, B. The duration of the Q-U interval and its components in electrocardiograms of normal persons. *American heart journal* **46**, 9–20 (1953).
49. Diemberger, I., Raschi, E. & Trifiro, G. Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies. *Clin Drug Investig*, <https://doi.org/10.1007/s40261-017-0563-7> (2017).
50. Poluzzi, E., Raschi, E., Diemberger, I. & De Ponti, F. Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice. *Drug safety* **40**, 461–464, <https://doi.org/10.1007/s40264-017-0529-y> (2017).

51. Lavange, L. M. *et al.* Sample design and cohort selection in the Hispanic Community Health Study/Study of Latinos. *Ann Epidemiol* **20**, 642–649, <https://doi.org/10.1016/j.annepidem.2010.05.006> (2010).
52. Sorlie, P. D. *et al.* Design and implementation of the Hispanic Community Health Study/Study of Latinos. *Ann Epidemiol* **20**, 629–641, <https://doi.org/10.1016/j.annepidem.2010.03.015> (2010).
53. Bild, D. E. Multi-Ethnic Study of Atherosclerosis: Objectives and Design. *American Journal of Epidemiology* **156**, 871–881, <https://doi.org/10.1093/aje/kw113> (2002).
54. Below, J. E. *et al.* Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. *Diabetologia* **54**, 2047–2055, <https://doi.org/10.1007/s00125-011-2188-3> (2011).
55. Anderson, G. L. *et al.* Implementation of the Women's Health Initiative study design. *Ann Epidemiol* **13**, S5–17 (2003).
56. Howie, B., Marchini, J. & Stephens, M. Genotype Imputation with Thousands of Genomes. *G3: Genes, Genomes, Genetics* **1**, 457–470, <https://doi.org/10.1534/g3.111.001198> (2011).
57. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191, <https://doi.org/10.1093/bioinformatics/btq340> (2010).
58. Avery, C. L. *et al.* Fine-Mapping and Initial Characterization of QT Interval Loci in African Americans. *PLoS Genet* **8**, e1002870, <https://doi.org/10.1371/journal.pgen.1002870> (2012).
59. Avery, C. L. *et al.* Fine mapping of QT interval regions in global populations refines previously identified QT interval loci and identifies signals unique to African and Hispanic descent populations. *Heart Rhythm* **14**, 572–580, <https://doi.org/10.1016/j.hrthm.2016.12.021> (2017).
60. Consortium, G. P. *et al.* An integrated map of genetic variation from 1,092 human genomes. *Nature* **491**, 56–65, <https://doi.org/10.1038/nature11632> (2012).
61. Sofer, T. *et al.* A powerful statistical framework for generalization testing in GWAS, with application to the HCHS/SOL. *Genet Epidemiol* **41**, 251–258, <https://doi.org/10.1002/gepi.22029> (2017).
62. ENCODE Project Consortium. The ENCODE (ENCyclopedia Of DNA Elements) Project. *Science* **306**, 636–640, <https://doi.org/10.1126/science.1105136> (2004).
63. Romanoski, C. E., Glass, C. K., Stunnenberg, H. G., Wilson, L. & Altmouzni, G. Epigenomics: Roadmap for regulation. *Nature* **518**, 314–316, <https://doi.org/10.1038/518314a> (2015).
64. Ward, L. D. & Kellis, M. HaploRegv4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. *Nucleic Acids Res* **44**, D877–881, <https://doi.org/10.1093/nar/gkv1340> (2016).

Acknowledgements

Hispanic Community Health Study/Study of Latinos (HCHS/SOL): We thank the participants and staff of HCHS/SOL study for their contributions to this study. The baseline examination of HCHS/SOL was carried out as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern University (N01-HC65236), and San Diego State University (N01-HC65237). The following Institutes/Centers/Offices contributed to the first phase of HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements. The Genetic Analysis Center at University of Washington was supported by NHLBI and NIDCR contracts (HHSN268201300005C AM03 and MOD03). Genotyping efforts were supported by NHLBI HSN 26220/20054 C, NCATS CTSI grant UL1TR000124, and NIDDK Diabetes Research Center (DRC) grant DK063491. AAS was supported by NHLBI Training grants T32HL7055 and T32HL07779. Multi-Ethnic Study of Atherosclerosis (MESA): This research was supported by the Multi-Ethnic Study of Atherosclerosis (MESA) contracts HHSN2682015000031, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169 and by grants UL1-TR-000040, UL1-TR-001079, and UL1-RR-025005 from NCRR. Funding for MESA SHARe genotyping was provided by NHLBI Contract N02-HL-6-4278. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. NS was supported by grants R01HL116747 and R01 HL111089. We also thank the other investigators, staff, and participants of MESA for their valuable contributions. A full list of participating MESA investigators and institutions can be found at <http://www.mesa-nhlbi.org>. Starr County: We thank the field staff in Starr County for collection of these data and are grateful to the study participants who gave their time and contributed to the study. This work was supported in part by grants DK073541, DK020595, AI085014, DK085501, and HL102830 from the National Institutes of Health and funds from the University of Texas Health Science Center at Houston. These studies (protocol SPH-02-042) were approved by the University of Texas Health Science Center at Houston's Committee for the Protection of Human Subjects and carried out in a manner consistent with the Declaration of Helsinki. The studies were explained to all participants and written informed consent obtained. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is funded through a federal contract from the National Institutes of Health (NIH) to The Johns Hopkins University, contract number HHSN268200782096C. Women's Health Initiative Clinical Trial (WHI CT): The Women's Health Initiative clinical trials were funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C.

Author Contributions

The authors have made the following contributions: conceived the study (R.M.G., S.M.G., K.F.K., M.P.C., T.S., E.A.W., H.J.L., C.L.H., C.C.L. and C.L.A.); designed the study (R.M.G., S.M.G., C.K., J.I.R., K.D.T., L.E.P., M.P.C., S.R.H., T.S., E.A.W., H.J.L., C.L.H., C.C.L. and C.L.A.); collected the data (C.K., E.Z.S., J.I.R., K.F.K., K.D.T., L.E.P.,

S.R.H., C.L.H. and C.C.L.); analyzed data (R.M.G., S.M.G., J.E.B., J.Y., A.A.S., H.M.H., C.K., E.Z.S., K.F.K., M.P.C., T.S., X.G., C.L.H., C.C.L. and C.L.A.); interpreted results (R.M.G., S.M.G., J.E.B., A.A.S., H.M.H., C.K., E.Z.S., K.F.K., M.P.C., N.S., S.C., T.S., E.A.W., H.J.L., C.L.H., C.C.L. and C.L.A.); drafted the paper (R.M.G., S.M.G., J.E.B., A.A.S., H.M.H., C.K., K.F.K., K.K.R., S.J.S., N.S., T.S., E.A.W., H.J.L., C.L.H., C.C.L. and C.L.A.); provided critical review (R.M.G., S.M.G., J.E.B., J.Y., A.A.S., H.M.H., C.K., E.Z.S., J.I.R., K.F.K., K.D.T., L.E.P., M.P.C., N.S., S.C., S.R.H., T.S., X.G., E.A.W., H.J.L., C.L.H., C.C.L. and C.L.A.); all authors approved manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-017-17136-0>.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017